Therapeutic Challenges In Chronic Lymphocytic Leukemia: A Case Report With 17p Deletion
Abstract
Background: Chronic lymphocytic leukemia (CLL) presents a very high clinical-biological heterogeneity, and the therapeutic choice depends on several parameters, primarily the evolutionary stage of the disease and the presence of molecular anomalies such as the 17p deletion. We report the case of a patient with CLL for whom the therapeutic choice was difficult to make despite well-established diagnostic and prognostic results. Case presentation: A 75-year-old patient presented with hyperlymphocytosis, a Matutes score of 5, and negative poor prognostic markers (ZAP70, CD38), corresponding to Binet stage B, for which therapeutic abstention with monitoring was initially decided. The lymphocyte count subsequently rose considerably, and the patient developed autoimmune hemolytic anemia (AIHA). The 17p deletion was then tested and found positive, leading to the initiation of Ibrutinib. A good clinical and biological response was observed until the patient developed complete arrhythmia due to atrial fibrillation, an unexpected cardiac complication that required discontinuing Ibrutinib. Venetoclax was chosen as the alternative treatment, with monitoring of disease progression under this new therapy. Conclusion: Despite a good biological diagnosis and a favorable prognostic assessment, the therapeutic choice for some patients with CLL is conditioned by other parameters, sometimes unrelated to the pathology itself or its progression, which forces the exclusion of therapies considered the most effective for these patients.